Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-16-0611
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Histone Butyrylation/ Acetylation Remains Unchanged in Triple Negative Breast Cancer Cells After a Long Term Metabolic Reprogramming

Asian Pacific Journal of Cancer Prevention
2019English

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2016English

Metabolic Consequences of HIF Silencing in a Triple Negative Human Breast Cancer Xenograft

Oncotarget
Oncology
2018English

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Triple-Negative Breast Cancer

2018English

Brachyury, a Vaccine Target, Is Overexpressed in Triple-Negative Breast Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2016English

A Review of Triple-Negative Breast Cancer

Cancer Control
MedicineOncologyHematology
2010English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Enzymatic De Novo Pyrimidine Nucleotide Synthesis

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy